The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2017 | Factors to consider in frontline and relapsed CLL before treatment
Barbara Eichhorst, MD from the University of Cologne, Cologne, Germany gives an overview factors that need to be considered when treating frontline and relapsed chronic lymphocytic leukemia (CLL). Dr Eichhorst explains that there are many factors to consider, such as the state of the disease, fitness, co-morbidities and the genetic profile of the patient. In the relapsed setting, it is also important to consider response to frontline therapy, duration of remission and genetic factors and co-morbidities.
Recorded at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK.
